<< Access to care issues, physician training, other problems contributing to mental health issues for elderly | Breast cancer incidence is lower for Latinas >>
Read in | English | हिन्दी

Sen. DeMint pledges to hold Von Eschenbach's FDA Commissioner nomination unless steps taken to take Mifeprex off market

Published on September 18, 2006 at 6:20 AM · No Comments

Sen. Jim DeMint (R-S.C.) plans to place a hold on President Bush's nomination of acting FDA Commissioner Andrew von Eschenbach to permanently head the agency unless "immediate steps" are taken to remove Danco Laboratories' medical abortion drug Mifeprex from the market, DeMint press secretary Wesley Denton said recently, the New York Times reports (Harris, New York Times, 9/15).

FDA in 2000 approved the sale of Mifeprex -- known generically as mifepristone -- to be used with misoprostol to induce a medical abortion, and more than 575,000 women have taken the drug since its approval, according to the National Abortion Federation. Experts in May called for more research into the causes of infection from the rare and potentially fatal bacterium Clostridium sordellii and other bacteria in women who were pregnant, some of whom took medical abortion drugs(Kaiser Daily Women's Health Policy Report, 5/12).

Senators Promise Holds

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading